CL2019001251A1 - Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartílagos. - Google Patents
Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartílagos.Info
- Publication number
- CL2019001251A1 CL2019001251A1 CL2019001251A CL2019001251A CL2019001251A1 CL 2019001251 A1 CL2019001251 A1 CL 2019001251A1 CL 2019001251 A CL2019001251 A CL 2019001251A CL 2019001251 A CL2019001251 A CL 2019001251A CL 2019001251 A1 CL2019001251 A1 CL 2019001251A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pyrido
- cartilage
- substituted indoles
- cartilage disorders
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title abstract 2
- 208000015100 cartilage disease Diseases 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 238000003786 synthesis reaction Methods 0.000 abstract 2
- 102000055008 Matrilin Proteins Human genes 0.000 abstract 1
- 108010072582 Matrilin Proteins Proteins 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A 9H PIRIDO[3,4-B]INDOLES SUSTITUIDOS CON 8-ARILO Y SUSTITUIDOS CON 8-HETEROARILO DE FÓRMULA I, EN LA QUE A, E, G, R1 A R6 Y R10 SON COMO SE DEFINEN EN LAS REIVINDICACIONES, QUE ESTIMULAN LA CONDROGÉNESIS Y LA SÍNTESIS DE LA MATRIZ DEL CARTÍLAGO Y SE PUEDEN USAR EN EL TRATAMIENTO DE TRASTORNOS Y AFECCIONES DEL CARTÍLAGO EN LOS QUE SE DESEA LA REGENERACIÓN DEL CARTÍLAGO DAÑADO, POR EJEMPLO, ENFERMEDADES DE LAS ARTICULACIONES TALES COMO LA OSTEOARTRITIS. LA INVENCIÓN SE REFIERE ADEMÁS A PROCEDIMIENTOS PARA LA SÍNTESIS DE LOS COMPUESTOS DE FÓRMULA I, SU USO COMO PRODUCTOS FARMACÉUTICOS, Y A COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306452.0A EP3318563A1 (en) | 2016-11-07 | 2016-11-07 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001251A1 true CL2019001251A1 (es) | 2019-10-04 |
Family
ID=57286428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001251A CL2019001251A1 (es) | 2016-11-07 | 2019-05-07 | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartílagos. |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US11130755B2 (es) |
| EP (3) | EP3318563A1 (es) |
| JP (1) | JP7046063B2 (es) |
| KR (1) | KR102490199B1 (es) |
| CN (1) | CN110382496B (es) |
| AR (1) | AR110136A1 (es) |
| AU (2) | AU2017353381B2 (es) |
| CA (1) | CA3042332A1 (es) |
| CL (1) | CL2019001251A1 (es) |
| CO (1) | CO2019005090A2 (es) |
| CR (1) | CR20190217A (es) |
| DK (1) | DK3535263T3 (es) |
| DO (1) | DOP2019000112A (es) |
| EA (1) | EA038365B1 (es) |
| EC (1) | ECSP19031458A (es) |
| ES (1) | ES2837765T3 (es) |
| HR (1) | HRP20201754T1 (es) |
| HU (1) | HUE052187T2 (es) |
| IL (1) | IL265982B (es) |
| LT (1) | LT3535263T (es) |
| MA (1) | MA45803B1 (es) |
| MX (1) | MX383580B (es) |
| MY (1) | MY189589A (es) |
| PE (1) | PE20191032A1 (es) |
| PH (1) | PH12019500997B1 (es) |
| PT (1) | PT3535263T (es) |
| RS (1) | RS61172B1 (es) |
| SG (1) | SG11201903195YA (es) |
| SI (1) | SI3535263T1 (es) |
| TN (1) | TN2019000143A1 (es) |
| TW (1) | TWI753966B (es) |
| UY (1) | UY37473A (es) |
| WO (1) | WO2018083157A1 (es) |
| ZA (1) | ZA201902111B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| US11547712B2 (en) | 2017-11-20 | 2023-01-10 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CA3086925A1 (en) | 2018-01-05 | 2019-07-11 | Ichan School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| CN112135613A (zh) * | 2018-03-20 | 2020-12-25 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| CN114269730A (zh) * | 2019-08-06 | 2022-04-01 | 多曼治疗学公司 | 作为神经肽ff受体拮抗剂的5-杂芳基-吡啶-2-胺化合物 |
| CN114763347B (zh) * | 2021-01-15 | 2024-06-21 | 华东师范大学 | 一类用于诱导间充质干细胞向软骨分化的化合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194747A (en) * | 1979-08-29 | 1988-11-29 | Schering Ag | 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives |
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| ECSP951529A (es) | 1995-09-05 | 1997-05-16 | Compuestos farmaceuticos | |
| EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| EP1134221A1 (en) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
| DE60217532T8 (de) | 2001-11-07 | 2008-02-07 | Millennium Pharmaceuticals, Inc., Cambridge | Carboline derivate als ikb-inhibitoren zur behandlung des m ultiplen myelomas |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| JP4626613B2 (ja) | 2004-08-04 | 2011-02-09 | コニカミノルタホールディングス株式会社 | 有機エレクトロルミネッセンス素子 |
| EP2054050B1 (en) | 2006-08-25 | 2012-08-08 | Ares Trading S.A. | Treatment of cartilage disorders with fgf-18 |
| WO2008132454A1 (en) | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| FR2916380B1 (fr) * | 2007-05-21 | 2009-07-31 | Saint Gobain | Procede et dispositif de surmoulage d'un element vitre par une portion de joint comportant un insert, vitrage et insert notamment pour ce procede. |
| WO2010038153A1 (en) | 2008-10-01 | 2010-04-08 | The University Of British Columbia | Use of sox transcription factor acti\ators for stimulating chondrogenesis |
| US9962368B2 (en) * | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2455378A1 (en) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| JP5854492B2 (ja) | 2011-02-24 | 2016-02-09 | 国立大学法人 岡山大学 | 軟骨細胞分化誘導促進剤 |
| UY35809A (es) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| JP2015107945A (ja) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | 神経新生に関する化合物及び医薬組成物 |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
-
2016
- 2016-11-07 EP EP16306452.0A patent/EP3318563A1/en not_active Withdrawn
-
2017
- 2017-11-02 CN CN201780081846.4A patent/CN110382496B/zh active Active
- 2017-11-02 CA CA3042332A patent/CA3042332A1/en active Pending
- 2017-11-02 HU HUE17794307A patent/HUE052187T2/hu unknown
- 2017-11-02 MA MA45803A patent/MA45803B1/fr unknown
- 2017-11-02 AU AU2017353381A patent/AU2017353381B2/en active Active
- 2017-11-02 PE PE2019000879A patent/PE20191032A1/es unknown
- 2017-11-02 ES ES17794307T patent/ES2837765T3/es active Active
- 2017-11-02 JP JP2019522912A patent/JP7046063B2/ja active Active
- 2017-11-02 PH PH1/2019/500997A patent/PH12019500997B1/en unknown
- 2017-11-02 CR CR20190217A patent/CR20190217A/es unknown
- 2017-11-02 HR HRP20201754TT patent/HRP20201754T1/hr unknown
- 2017-11-02 RS RS20201512A patent/RS61172B1/sr unknown
- 2017-11-02 MX MX2019005308A patent/MX383580B/es unknown
- 2017-11-02 KR KR1020197016225A patent/KR102490199B1/ko active Active
- 2017-11-02 DK DK17794307.3T patent/DK3535263T3/da active
- 2017-11-02 WO PCT/EP2017/078026 patent/WO2018083157A1/en not_active Ceased
- 2017-11-02 EP EP20198613.0A patent/EP3792262A1/en active Pending
- 2017-11-02 EP EP17794307.3A patent/EP3535263B1/en active Active
- 2017-11-02 EA EA201991144A patent/EA038365B1/ru unknown
- 2017-11-02 US US16/347,386 patent/US11130755B2/en active Active
- 2017-11-02 MY MYPI2019001925A patent/MY189589A/en unknown
- 2017-11-02 SG SG11201903195YA patent/SG11201903195YA/en unknown
- 2017-11-02 TN TNP/2019/000143A patent/TN2019000143A1/en unknown
- 2017-11-02 SI SI201730476T patent/SI3535263T1/sl unknown
- 2017-11-02 PT PT177943073T patent/PT3535263T/pt unknown
- 2017-11-02 LT LTEP17794307.3T patent/LT3535263T/lt unknown
- 2017-11-03 TW TW106138038A patent/TWI753966B/zh active
- 2017-11-07 UY UY0001037473A patent/UY37473A/es not_active Application Discontinuation
- 2017-11-07 AR ARP170103083A patent/AR110136A1/es active IP Right Grant
-
2019
- 2019-04-04 ZA ZA2019/02111A patent/ZA201902111B/en unknown
- 2019-04-11 IL IL265982A patent/IL265982B/en active IP Right Grant
- 2019-05-02 DO DO2019000112A patent/DOP2019000112A/es unknown
- 2019-05-06 EC ECSENADI201931458A patent/ECSP19031458A/es unknown
- 2019-05-07 CL CL2019001251A patent/CL2019001251A1/es unknown
- 2019-05-17 CO CONC2019/0005090A patent/CO2019005090A2/es unknown
-
2021
- 2021-08-23 US US17/409,513 patent/US11827633B2/en active Active
- 2021-08-24 AU AU2021221468A patent/AU2021221468B2/en active Active
-
2023
- 2023-10-17 US US18/488,871 patent/US12275733B2/en active Active
-
2025
- 2025-03-03 US US19/068,406 patent/US20250333412A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001251A1 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartílagos. | |
| CL2018001624A1 (es) | Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| SV2016005311A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CL2013003731A1 (es) | Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad. | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| CR20200484A (es) | COMPUESTOS DE DIHIDROISOQUINOLINONA SUSTITUIDA (Divisional 2016-0574) | |
| CO6670575A2 (es) | Aminopirazoloqinazolinas sustituidas, útiles en el tratamiento de enfermedades proliferativas y composiciones farmaceúticas que las continen | |
| UY36226A (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| MX2016014854A (es) | Compuestos y composiciones para inducir condrogenesis. | |
| PE20170088A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| CL2016002245A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| NI202000029A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| MX2019003026A (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| CL2017000040A1 (es) | Inhibidores de aldosterona sintasa. | |
| MX2020001157A (es) | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| MX384987B (es) | Derivados del ácido acético azaindol y su uso como moduladores de receptor de prostaglandina d2. | |
| UY35600A (es) | "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas" | |
| ECSP17003149A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| CO2017003225A2 (es) | Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos |